Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 3/20 | 0.51 |
| ▸ | DRD4 | P21917 | 3/20 | 0.51 |
| ▸ | DRD3 | P35462 | 3/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 3/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1264072 | 1.00 | RECQL (0.52) | RECQLSMN1; SMN2DRD2DRD4DRD3 | |
| SCHEMBL2395111 | 0.91 | RECQL (0.62) | RECQLSMN1; SMN2DRD2DRD4DRD3 | |
| SCHEMBL3563415 | 0.84 | DRD2 (0.57) | RECQLSMN1; SMN2DRD2DRD4DRD3 | |
| SCHEMBL2327650 | 0.84 | DRD2 (0.57) | RECQLSMN1; SMN2DRD2DRD4DRD3 | |
| SCHEMBL238565 | 0.84 | DRD2 (0.57) | RECQLSMN1; SMN2DRD2DRD4DRD3 | |
| SCHEMBL13443303 | 0.84 | MC4R (0.60) | RECQLSMN1; SMN2DRD2DRD4DRD3 | |
| SCHEMBL6584141 | 0.83 | DRD2 (0.55) | RECQLSMN1; SMN2DRD2DRD4DRD3 | |
| SCHEMBL4278988 | 0.83 | DRD2 (0.55) | RECQLSMN1; SMN2DRD2DRD4DRD3 | |
| SCHEMBL2322360 | 0.83 | DRD2 (0.55) | RECQLSMN1; SMN2DRD2DRD4DRD3 | |
| SCHEMBL2202542 | 0.81 | DRD4 (0.53) | RECQLSMN1; SMN2DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066662-B1 | SERINE HYDROLASE INHIBITORS | KYORIN SEIYAKU KK (JP) | 2012-12-05 | — | — | EP | disclosed |
| US-7879846-B2 | e.g. 2-(2-Imidazol-1-yl-pyridin-3-yl)-5-methyl-4H-benz[d][1,3]oxazin-4-one ; neutrophil elastase inhibitor; antiinflammatory agent, respiratory system disorders | Kyorin Pharmaceutical Co.., Ltd. (JP) | 2011-02-01 | — | — | US | disclosed |
| EP-2066662-A2 | SERINE HYDROLASE INHIBITORS | Activx Biosciences, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20080161290-A1 | Serine hydrolase inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| WO-2008036379-A2 | SERINE HYDROLASE INHIBITORS | ACTIVX BIOSCIENCES, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161290-A1 | Serine hydrolase inhibitors | SERPINB1, ELANE, EPX | RECQL 418/4885SMN1; SMN2 930/4885DRD2 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.